|
Laurence N. Raymond, Ph.D. is a Co-Founder of ReceptoPharm. From 1997 to May 2001, Dr. Raymond was a consultant to BioTherapeutics, Inc., also known as Phylomed, Inc., where he was instrumental in the development of monoclonal antibodies utilized in the investigation of modified toxins as well as the development of cell culture, immunochemical and receptor based assays for examination of the therapeutic applications of biopharmaceuticals. Previously, Dr. Raymond was an Associate Fellow at the Sandoz Research Institute, a division of Sandoz Pharmaceuticals, where he established and managed a laboratory developing monoclonal antibody-based immunoassays. Prior to that Dr. Raymond was Manager of Research and Development for Pel-Freez Biologicals in Rogers, Arkansas, and, simultaneously, Director of the Hybridoma Lab at the University of Arkansas Biotechnology Center in Fayetteville, Arkansas. There he was responsible for establishing and producing monoclonal antibody under contract. Dr. Raymond developed techniques in hybridoma creation and development as well as protein purification and lymphoid stimulation while at the University of New Mexico School of Medicine in Albuquerque. While at the Biophysics Technology Laboratory, at the University of Arizona in Tucson, he developed an adjunct system to plasmaphoresis for the extra-corporal removal of plasma proteins by electrodialysis to be applied to the treatment of Waldenstrom's macroglobulinemia and was applied to the model disease in dogs. He was involved in rheumatoid arthritis research with the Southwestern Clinic and Research Institute in Tucson, Arizona, where he developed his skills in tissue and cell culture, mitogenic and antigenic stimulation of lymphoid cells as well as in-vitro and radio-assays. Dr. Raymond earned a Bachelor's Degree in Nutritional Biochemistry, a Master's of Science Degree in Animal Physiology and a Ph.D. in Microbiology and Immunology all from the University of Arizona. | 